Insider buying · SEC Form 4

Insider Buying — Jul 21, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

2insider buys
$9.08Mbought in total
2companies
1by CEOs, CFOs and other chiefs
COElargest: $8.48M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
COEChina Online Education GroupJack Jiajia HuangCEO$8.48M495,360$17.12AddedJul 20, 2026
Form 4 ↗
Late filing: transactions July 9–13 at $17.19/$16.71/$17.24 per tranche. Via HH Talent Limited (CEO personal vehicle) under 10b5-1 plan adopted Dec 25, 2025. Current price $16.50 (-3.6% from avg buy of ~$17.12). Active accumulation campaign.
FULCFulcrum Therapeutics, Inc.Kevin Tang10% Owner$594K167,616$3.55AddedJul 20, 2026
Form 4 ↗
Jul 16: 116,671 shares @ $3.56 avg; Jul 17: 50,945 shares @ $3.52 avg. Indirect via Tang Capital Partners LP & affiliates. Post-purchase total: 7,080,945 shares. Prior tranche ~$891K filed Jul 15. Current price $3.62 (+2.3% from avg buy ~$3.54).

AIThe day in insider buying

SEC Form 4 Insider Scan — July 21, 2026

Scanned the last 24 hours of EDGAR Form 4 filings. 2 qualifying buys (≥ $250K, transaction type P) totalling $9.1M.

Headline Filings

  • COE — Jack Jiajia Huang (CEO) bought 495,360 shares ≈ $8.48M at ~$17.12 avg (via HH Talent Limited, 10b5-1); now $16.50 (-3.6% since buy). (filing)
  • FULC — Kevin Tang (10% Owner / Tang Capital) bought 167,616 shares ≈ $594K at ~$3.54 avg; now $3.62 (+2.3% since buy). (filing)

Notes

COE (51Talk/China Online Education Group): Late filing — transactions occurred July 9–13 but Form 4 filed July 20. CEO purchased under a Rule 10b5-1 plan adopted December 25, 2025 via personal vehicle HH Talent Limited. Stock currently underwater vs. the buy price by ~3.6%.

FULC (Fulcrum Therapeutics): Kevin Tang continues to accumulate at $3.52–$3.56 range, adding to an existing 7M+ share position. Tang Capital is a known concentrated biotech investor; this is part of a multi-week accumulation campaign (prior tranche ~$891K filed July 15). Stock is slightly in the green vs. the buy price.

Notable exclusions: CBIO (Crescent Biopharma) — P-coded $20M was participation in company's $143.7M public offering, not secondary-market buy. LNBIX (Lincoln Financial/Lincoln Bain) — $25M was investment adviser adding to managed trust, not traditional insider.

Most-bought stocks, last 30 days

  • AVO $74.5M · 14 buys, 4 insidersMission Produce, Inc.
  • COE $12.1M · 3 buysChina Online Education Group
  • PBLS $10.0M · 1 buyParabilis Medicines, Inc.
  • PSEC $9.35M · 3 buys, 2 insidersProspect Capital Corp
  • NTSK $7.53M · 2 buys, 2 insidersNetskope Inc.
  • HDSN $6.10M · 2 buys, 2 insidersHudson Technologies, Inc.
  • STEP $5.02M · 1 buyStepStone Group Inc.
  • NVCT $4.66M · 8 buys, 2 insidersNuvectis Pharma, Inc.
  • ARTV $4.60M · 1 buyArtiva Biotherapeutics Inc.
  • ENR $3.71M · 3 buys, 2 insidersEnergizer Holdings, Inc.
  • GLOO $3.50M · 1 buyGloo Holdings, Inc.
  • WBX $2.25M · 2 buys, 2 insidersWallbox N.V.
  • GGAL $2.09M · 1 buyGrupo Financiero Galicia S.A.
  • AMR $2.01M · 1 buyAlpha Metallurgical Resources Inc.
  • NXST $1.99M · 1 buyNexstar Media Group, Inc.
  • ADBE $1.95M · 1 buyAdobe Inc
  • RH $1.83M · 1 buyRH
  • JCTC $1.61M · 2 buys, 2 insidersJewett-Cameron Trading Co. Ltd.
  • FULC $1.48M · 2 buys, 2 insidersFulcrum Therapeutics, Inc.
  • FISV $1.37M · 3 buys, 3 insidersFiserv Inc.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.